pep005 (pkc activator) Search Results


pep005 (pkc activator)  (Cayman Chemical)
90
Cayman Chemical pep005 (pkc activator)
(A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 –infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM <t>PEP005</t> or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9 but analysis continued for an additional 8 weeks. (C) Log-rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (Exp. 1) from experiments shown in . (E–F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 ( E ) and intracellular p24 levels ( F ) were analyzed on day 6 after stimulation. Asterisk (*) denotes below detection limit.
Pep005 (Pkc Activator), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pep005+%28pkc+activator%29/bio_rxiv__842419-156-0-6?v=Cayman+Chemical
Average 90 stars, based on 1 article reviews
pep005 (pkc activator) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
endothelin-1 antibody (3d6)  (Bio-Techne corporation)
92
Bio-Techne corporation endothelin-1 antibody (3d6)
(A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 –infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM <t>PEP005</t> or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9 but analysis continued for an additional 8 weeks. (C) Log-rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (Exp. 1) from experiments shown in . (E–F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 ( E ) and intracellular p24 levels ( F ) were analyzed on day 6 after stimulation. Asterisk (*) denotes below detection limit.
Endothelin 1 Antibody (3d6), supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pep005+%28pkc+activator%29/bio-techne+corporation___h00001906-m01?v=Bio-Techne+corporation
Average 92 stars, based on 1 article reviews
endothelin-1 antibody (3d6) - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

Image Search Results


(A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 –infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM PEP005 or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9 but analysis continued for an additional 8 weeks. (C) Log-rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (Exp. 1) from experiments shown in . (E–F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 ( E ) and intracellular p24 levels ( F ) were analyzed on day 6 after stimulation. Asterisk (*) denotes below detection limit.

Journal: bioRxiv

Article Title: A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1101/842419

Figure Lengend Snippet: (A) Assay overview. Schematic representation of the assay protocol involving the HIV-1 NL4-3 –infected cell culture model (Jurkat/NL cells). (B) Changes in supernatant p24 levels without drugs, with 5 nM PEP005 or 50 nM EFdA, or with a combination of 50 nM EFdA and 5 nM PEP005 (n = 11, 9, 11, and 11, respectively). Drug treatment was terminated on week 9 but analysis continued for an additional 8 weeks. (C) Log-rank test comparison of the percentage of non-recurrence in the EFdA single treatment and the combination treatment. (D) Changes in supernatant p24 levels in a representative experiment (Exp. 1) from experiments shown in . (E–F) Assessment of the viral rebound in Jurkat/NL cells after drug discontinuation. Cells treated with drugs or untreated cells were stimulated with TNF-α (10 ng/mL) in week 17, and supernatant p24 ( E ) and intracellular p24 levels ( F ) were analyzed on day 6 after stimulation. Asterisk (*) denotes below detection limit.

Article Snippet: PEP005 (PKC activator) was purchased from Cayman Chemical (Ann Arbor, MI); SAHA (vorinostat; HDAC inhibitor) from Santa Cruz Biotechnology (Dallas, TX); JQ-1 (BRD4 inhibitor) from BioVision (Milpitas, CA); GSK525762A (BRD4 inhibitor) from ChemScene (Monmouth Junction, NJ); Ro5-3335 from Merck (Darmstadt, Germany); and Al-10-49 (CBFβ/RUNX inhibitor) from Selleck (Houston, TX).

Techniques: Infection, Cell Culture

(A) Fitting of the mathematical model to the experimental data in WIPE assay without and with antiviral drug(s): numbers of uninfected and latently infected cells (cells/ml), virus producing cells (cells/ml), supernatant p24 (pg/ml), and normalized proviral DNA. The shadowed regions corresponded to 95% posterior predictive intervals, the solid lines gave the best-fit solution (mean) for the mathematical model, and the colored dots showed the experimental datasets. All data were fitted simultaneously. (B) The distribution for the time until reactivation without and with PEP005-treatment calculated from all accepted MCMC parameter estimates are shown in green and blue, respectively. These lengths were significantly shorter with PEP005-treatment than without treatment as assessed by the repeated bootstrap t -test.

Journal: bioRxiv

Article Title: A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1101/842419

Figure Lengend Snippet: (A) Fitting of the mathematical model to the experimental data in WIPE assay without and with antiviral drug(s): numbers of uninfected and latently infected cells (cells/ml), virus producing cells (cells/ml), supernatant p24 (pg/ml), and normalized proviral DNA. The shadowed regions corresponded to 95% posterior predictive intervals, the solid lines gave the best-fit solution (mean) for the mathematical model, and the colored dots showed the experimental datasets. All data were fitted simultaneously. (B) The distribution for the time until reactivation without and with PEP005-treatment calculated from all accepted MCMC parameter estimates are shown in green and blue, respectively. These lengths were significantly shorter with PEP005-treatment than without treatment as assessed by the repeated bootstrap t -test.

Article Snippet: PEP005 (PKC activator) was purchased from Cayman Chemical (Ann Arbor, MI); SAHA (vorinostat; HDAC inhibitor) from Santa Cruz Biotechnology (Dallas, TX); JQ-1 (BRD4 inhibitor) from BioVision (Milpitas, CA); GSK525762A (BRD4 inhibitor) from ChemScene (Monmouth Junction, NJ); Ro5-3335 from Merck (Darmstadt, Germany); and Al-10-49 (CBFβ/RUNX inhibitor) from Selleck (Houston, TX).

Techniques: Infection

(A) Quantification of intracellular copies of HIV-1 DNA at each time point in Exp. 6 (fig. S3A). (B) Schematic representation of the individual provirus structures from two different treatment groups and at two time points in Exp. 6. Each horizontal bar represents an individual HIV-1 genome, as determined by amplification of near full-length HIV-1 DNA from a single HIV-1 genome and DNA sequencing. The gray bars denote full-length types and the red bars indicate defective proviruses. (C) Pie charts reflecting the proportion of defective and intact proviruses in Exp. 6. (D) Pie charts reflecting the proportion of defective and intact proviruses in PBMCs from three HIV-infected individuals. ( E ) Quantification of intracellular copies of HIV-1 DNA at each time point in Exp. 1 . (F) Schematic representation of the individual provirus structures in Exp. 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. (G) Pie chart showing the relative abundance of each HIV-1-infected clone. Chromosomal number and position of each clone is shown in the right panel. ( H) Schematic figure of the provirus structure and IS in the expanded clone. A 467-bp deletion in the 5′-end of 5′LTR was observed. TSS, transcription start site. Asterisk (*) stands for below detection limit.

Journal: bioRxiv

Article Title: A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

doi: 10.1101/842419

Figure Lengend Snippet: (A) Quantification of intracellular copies of HIV-1 DNA at each time point in Exp. 6 (fig. S3A). (B) Schematic representation of the individual provirus structures from two different treatment groups and at two time points in Exp. 6. Each horizontal bar represents an individual HIV-1 genome, as determined by amplification of near full-length HIV-1 DNA from a single HIV-1 genome and DNA sequencing. The gray bars denote full-length types and the red bars indicate defective proviruses. (C) Pie charts reflecting the proportion of defective and intact proviruses in Exp. 6. (D) Pie charts reflecting the proportion of defective and intact proviruses in PBMCs from three HIV-infected individuals. ( E ) Quantification of intracellular copies of HIV-1 DNA at each time point in Exp. 1 . (F) Schematic representation of the individual provirus structures in Exp. 1 for the EFdA/PEP005 culture group 17 weeks after drug treatment initiation. (G) Pie chart showing the relative abundance of each HIV-1-infected clone. Chromosomal number and position of each clone is shown in the right panel. ( H) Schematic figure of the provirus structure and IS in the expanded clone. A 467-bp deletion in the 5′-end of 5′LTR was observed. TSS, transcription start site. Asterisk (*) stands for below detection limit.

Article Snippet: PEP005 (PKC activator) was purchased from Cayman Chemical (Ann Arbor, MI); SAHA (vorinostat; HDAC inhibitor) from Santa Cruz Biotechnology (Dallas, TX); JQ-1 (BRD4 inhibitor) from BioVision (Milpitas, CA); GSK525762A (BRD4 inhibitor) from ChemScene (Monmouth Junction, NJ); Ro5-3335 from Merck (Darmstadt, Germany); and Al-10-49 (CBFβ/RUNX inhibitor) from Selleck (Houston, TX).

Techniques: Amplification, DNA Sequencing, Infection